Valuation: Prothena Corporation plc

Market Cap 453M 396M 366M 337M 635M 43.66B 649M 4.37B 1.72B 21.38B 1.7B 1.67B 73.61B P/E 2026 *
186x
P/E 2027 * -8.41x
Enterprise Value 453M 396M 366M 337M 635M 43.66B 649M 4.37B 1.72B 21.38B 1.7B 1.67B 73.61B EV / Sales 2026 *
5.44x
EV / Sales 2027 * 20.6x
Free-Float
79.82%
Yield 2026 *
-
Yield 2027 * -
1 day+2.24%
1 week-6.28%
Current month-11.54%
1 month+2.00%
3 months-20.55%
6 months-7.38%
Current year-9.32%
1 week 8.08
Extreme 8.075
9.19
1 month 8.08
Extreme 8.075
10.15
Current year 7.73
Extreme 7.73
11.8
1 year 6.24
Extreme 6.24
11.8
3 years 4.32
Extreme 4.32
70.28
5 years 4.32
Extreme 4.32
79.75
10 years 4.32
Extreme 4.32
79.75
Manager TitleAgeSince
Chief Executive Officer 57 30/09/2016
Director of Finance/CFO 52 01/04/2013
Chief Tech/Sci/R&D Officer 53 01/01/2015
Director TitleAgeSince
Director/Board Member 72 20/12/2012
Director/Board Member 57 30/09/2016
Director/Board Member 82 22/07/2013
Date Insider Type Main position Quantity % Market Cap.
6/16/26 A Buy 20,000 0.0382%
6/15/26 A Don -325,000 0.6208%
6/11/26 A Buy 125,000 0.2388%
Change 5-day change 1-year change 3-year change Capi.($)
+2.24%-6.28%+33.85%-87.73% 443M
-7.17%-4.39%+45.51%+79.00% 55.98B
+0.24%-1.54%+53.22%+71.85% 53.69B
+0.80%-6.31%+3.98%+423.29% 23.29B
-0.09%-0.01%-17.62%-14.67% 23.15B
-5.95%-2.58%+30.67%-9.58% 20.58B
-1.14%+0.03%+31.57%-30.42% 17.76B
-5.16%-7.00%+168.44%+306.37% 16.09B
-6.91%-5.83%+26.53%+636.97% 15.93B
+0.43%-1.03%+24.63%+191.40% 14B
Average -2.27%-0.75%+40.08%+156.65% 24.09B
Weighted average by Cap. -2.91%-0.74%+40.57%+144.36%

Financials

2026 *2027 *
Net sales 83.32M 72.81M 67.19M 61.93M 117M 8.02B 119M 803M 316M 3.93B 313M 306M 13.53B 22M 19.23M 17.74M 16.35M 30.82M 2.12B 31.51M 212M 83.4M 1.04B 82.62M 80.81M 3.57B
Net income 2.42M 2.12M 1.95M 1.8M 3.4M 233M 3.47M 23.36M 9.19M 114M 9.1M 8.9M 393M -55.93M -48.87M -45.1M -41.57M -78.35M -5.39B -80.09M -539M -212M -2.64B -210M -205M -9.08B
Net Debt - -
Logo Prothena Corporation plc
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Employees
67
Date Price Change Volume
17/07/26 $8.660 +2.24% 397,186
16/07/26 $8.470 +0.47% 659,662
15/07/26 $8.430 -2.43% 504,691
14/07/26 $8.640 -2.15% 530,318
13/07/26 $8.830 -4.44% 781,732
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
8.660USD
Average target price
21.40USD
Spread / Average Target
+147.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRTA Stock